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Hepatocytes express an array of plasmamembrane and intracellular ion channels, yet their role during the hepatitis C virus
(HCV) life cycle remains largely undefined. Here, we show that HCV increases intracellular hepatic chloride (Cl) influx that can
be inhibited by selective Cl channel blockers. Through pharmacological and small interfering RNA (siRNA)-mediated silenc-
ing, we demonstrate that Cl channel inhibition is detrimental to HCV replication. This represents the first observation of the
involvement of Cl channels during the HCV life cycle.
Hepatitis C virus (HCV) is a major human pathogen thatcauses chronic liver disease, including hepatocellular carci-
noma and cirrhosis (1). Between 130 and 170 million people are
now chronically infected, and HCV-related disease leads to
350,000 deaths per year (2). Recent developments have led to the
discovery of new direct-acting antivirals (DAA) (3), including the
HCV polymerase (NS5B) inhibitor sofosbuvir. While these DAAs
signify the encouraging progress of HCV treatment regimens, is-
sues of their high cost coupled with potential resistance remain.
Thus, research into new antiviral targets is still required (4).
HCV is an enveloped virus with a positive-sense, single-
stranded RNA genome belonging to the genus Hepacivirus
within the Flaviviridae family (5, 6). The 9.6-kb HCV genome
encodes a single large polyprotein of 3,000 amino acids, which is
processed by viral and host cellular proteases into 10 functional
proteins (6, 7). These include the structural proteins (core, E1, E2)
and seven nonstructural proteins (p7, NS2, NS3, NS4A, NS4B,
NS5A, NS5B) (6).
HCV displays tropism primarily for hepatocytes, the paren-
chymal cells of the liver (6, 8). Hepatocytes are multifunctional
epithelial cells that engage in transcellular solute transport, pro-
cessing of metabolites, and the synthesis and secretion of numer-
ous important proteins. In common with all eukaryotic cells,
hepatocytes possess ion channels at the plasma membrane and in
multiple intracellular compartments (9, 10). We have previously
shown that HCV NS5A can inhibit a hepatic proapoptotic host
cell K channel (Kv2.1, KCNB1) to maintain the survival of in-
fected cells (10) by perturbing signaling leading to Kv2.1 activa-
tion (11). There are over 230 genes encoding ion channel subunits
in the human genome (12), but no further functional role of these
channels during HCV pathogenesis has been assigned. We there-
fore assessed the effects of modulating all the major cellular ion
channel families on the HCV life cycle.
To determine if the activities of cellular ion channels are re-
quired during the HCV life cycle, we first assessed virus genome
replication using the bicistronic JFH-1 genotype 2a subgenomic
replicon (SGR), which expresses a firefly luciferase-neomycin
phosphotransferase fusion protein (SGR–Feo–JFH-1) (13). A cell
line stably harboring this SGR was treated with compounds pre-
viously characterized as modulating specific ion channel families.
Replication was monitored through the measurement of lucifer-
ase activity and confirmed by Western blotting for NS5A. Dacla-
tasvir (DCV) was included as a known inhibitor of virus replica-
tion (14); it reduced luciferase activity by 94% 5% (Fig. 1A) and
reduced NS5A expression to undetectable levels. As shown in Fig.
1B to D, there were no effects on luciferase activity or NS5A ex-
pression when cells were treated with tetraethylammonium
(TEA), a broadly acting blocker of potassium (K) channels (15),
4-aminopyridine (4AP), a blocker of voltage-gated K channels
(16), or KCl to collapse K gradients. Similarly, when cells were
treated with blockers of voltage-gatedNa channels (NaV), tetro-
dotoxin (TTX), disopyramide phosphate (DP), and lidocaine (17,
18) or with inhibitors of plasma membrane Ca2 channels,
namely, nifedipine (Nif) and nimodipine (Nim) (19), no reduc-
tion in genome replication 24 h after compound treatment oc-
curred (Fig. 1B to D). We thus concluded that the inhibition of
K, Na, and Ca2 channels does not have an impact on HCV
genome replication.
At the hepatocyte plasma membrane, Cl channels are abso-
lutely required for cell volume control and apoptosis regulation
(9, 10). Intracellularly, Cl transport across organelle membranes
is involved in endosomal, lysosomal, and Golgi apparatus acidifi-
cation (20, 21). We assessed several well-characterized Cl chan-
nel blockers, including 5-nitro-2-3-phenylpropylamino benzoic
acid (NPPB), indyanyloxyacetic acid 94 (IAA-94), and diisothio-
cyanostilbene-2,20-disulfonic acid (DIDS) for their effects on
SGR–Feo–JFH-1 replication. Figure 2A shows that NPPB and
IAA-94 significantly inhibited HCV genome replication (10 M,
57.7%  8% inhibition, and 100 M, 62%  3% inhibition, re-
spectively) and reduced NS5A expression, as assessed by Western
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blotting (Fig. 2C) and indirect immunofluorescence analysis (Fig.
2D). At these inhibitory concentrations, NPPB and IAA-94 did
not affect cell viability (Fig. 2A, gray bars) or HCV internal ribo-
some entry site (IRES)-mediated translation (Fig. 2B), suggesting
a specific inhibition of virus genome replication. The inhibitory
effects of NPPB and IAA-94 were also confirmed in a genotype
1B-derived replicon (SGR-Feo-Con1) (63%  23% and 56% 
27% inhibition, respectively), suggesting these effects to be con-
served across genotypes (Fig. 2E). Surprisingly, DIDS, awell-char-
acterized broadly acting inhibitor of anion exchangers, did not
inhibit SGR replication (Fig. 2A to E). We reasoned that HCV
genome replication is thus dependent on the function of an
NPPB- and IAA-94-sensitive, DIDS-insensitive Cl channel. Sev-
eral Cl channels with this pharmacological profile have been
reported (22). Given these effects, we proceeded to examine Cl
homeostasis during the HCV replication cycle. For this, we used
the fluorescent indicator N-ethoxycarbonylmethyl-6-methoxy-
quinolinium bromide (MQAE), a dye quenched by enhanced Cl
influx and the subsequent increase in intracellular chloride con-
centration [Cl]i. Figure 2F demonstrates that SGR–Feo–JFH-1-
harboring cells display a 42% increase in [Cl]i compared to the
level in parental Huh7 cells (gray bars), consistent with an
FIG 1 Assessment of ion channel modulators on HCV replication. SGR–Feo–JFH-1 cells stably expressing a luciferase subgenomic replicon (genotype 2a) were
treated with DCV (1 M) (A) or the indicated K (10 mM TEA, 40 mMKCl, 1 mM 4AP) (B), Na (5 MTTX, 100 Mdisopyramide phosphate [DP], 1 mM
lidocaine) (C), orCa2 (5Mnifedipine, 5Mnimodipine) (D) channelmodulators for 24 h. Luciferase activity (relative luminescence units [RLU] per second)
was used as a measure of genome replication (black bars), and cell viability was assessed by 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide
(MTT) assays (gray bars). Results were calculated relative to those for an untreated control. Error bars represent the standard errors of themeans (SEM) of results
from three independent experiments. **, significant difference from the control value (P 0.05); NS, no differences at a significance level of 0.05. Immunoblots
of cell lysates 48 h after the drug treatment were analyzed with polyclonal anti-NS5A antiserum or anti-GAPDH (glyceraldehyde-3-phosphate dehydrogenase;
loading control). Representative Western blots are shown below each corresponding graph. Con, control; Lid, lidocaine; Nif, nifedipine; Nim, nimodipine.
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enhanced basally active Cl inward conductance. The [Cl]i
increase could be suppressed by prolonged treatment with
NPPB (10 M, 24 h), which reduced [Cl]i to levels compara-
ble to those in untreated Huh7 cells (Fig. 2F, white bars). Taken
together, these data confirm that SGR–Feo–JFH-1 cells possess
enhanced transepithelial Cl transport through an NPPB-sen-
sitive Cl channel.
Since SGR–Feo–JFH-1-harboring cells express only the HCV
FIG 2 Assessment of the role of Cl channels during HCV replication. (A) JFH-1–SGR-Feo cells were treated with the Cl channel inhibitors NPPB (10 M),
IAA-94 (100 M), and DIDS (100 M) for 24 h, and luciferase expression was assessed as described for Fig. 1. Results were calculated relative to those for an
untreated control. Error bars represent the SEM from three independent experiments. **, significant difference from the value for the untreated control (P
0.05); NS, no differences at the 0.05 significance level. (B) Huh7 cells were transfected with either the pRZF vector (mock control) or the pRZF vector containing
the firefly luciferase gene under the translational control of theHCVor the encephalomyocarditis virus (EMCV) IRES and the promoter-drivenRenilla luciferase
gene as previously described (10). Four hours posttransfection, cells were treated with DCV, IAA-94, NPPB, and DIDS for 48 h, and luciferase expression was
assessed as described for Fig. 1. Error bars represent the SEM from three independent experiments. Values are normalized to theRenilla luciferase values to assess
effects on translation. (C) Sample Western blots immunoblotted for NS5A and GAPDH (loading control) are shown. SGR–Feo–JFH-1 cells were treated with
DCV,NPPB, IAA-94, orDIDS for 48 h. (D) SGR–Feo–JFH-1 cells were treatedwith the indicatedClblockers; 48 h posttreatment, theywere fixedwithmethanol
and permeabilized in 50% methanol-acetone. NS5A was visualized via labeling with sheep anti-NS5A antisera followed by staining with Alexa Fluor 488-
conjugated secondary antibodies. Representative confocal images are shown. (E) SGR-Feo-Con1 cells stably expressing a luciferase subgenomic replicon
(genotype 1b) were treated with the Cl channel inhibitors, and luciferase activity was assessed as described for panel A. Error bars represent the SEM of results
of stimulations from three independent experiments. **, significant difference from the value for the untreated control (P 0.05). NS, no differences at the 0.05
significance level. (F) Naive Huh7 and SGR-Neo-JFH-1 cells were seeded into 12-well plates and treated for the indicated times with 10MNPPB and then were
loaded with 5mM6-methoxy-quinolyl acetoethyl ester (MQAE) inDulbeccomodified Eaglemedium (DMEM) for 1 h at 37°C. Following incubation, cells were
washed three times with DMEM and fluorescent images immediately acquired using the IncuCyte Zoom live-cell imager. Mean fluorescence per cell was
calculated from a minimum of three independent experiments performed in triplicate using IncuCyte Zoom live-cell imager software.
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nonstructural proteins NS3 to NS5B, it was important to deter-
minewhetherCl channel inhibition suppressedHCVreplication
in the context of virus-infected cells (23). We initially used a
monocistronic full-length HCV chimeric genotype 2a virus, J6/
JFH1, which is fully infectious in cell culture and expresses Renilla
luciferase, herein termed J6/JFH-1 RLuc (24). Assays were per-
formed by virus infection (multiplicity of infection [MOI] of 0.5)
in the presence of each channel modulator, and luciferase expres-
sion was analyzed 48 h postinfection (p.i.). Figure 3A shows that
NPPB and IAA-94 treatment significantly decreased J6/JFH-1
RLuc activity (67%  20% and 63%  5% inhibition, respec-
tively) confirming a dependence onCl influx during the virus life
cycle. When these assays were performed in the presence of DIDS
(100M), J6/JFH-1 RLuc activity also decreased by 77% 4% at
concentrations that did not affect SGR–Feo–JFH-1 replication
(Fig. 3A). To verify these data, we directly infectedHuh7 cells with
full-length JFH-1 virus (25) in the presence of each Cl inhibitor
andmeasured the production of infectious virions by focus-form-
ing assay. As shown in Fig. 3B, virus yields were significantly lower
in IAA-94-, NPPB-, and DIDS-treated cells (87% 14%, 81%
FIG 3 Assessment of the role of Cl channels during HCV infection. (A) Huh7 cells were pretreated with the indicated inhibitors for 45 min and infected with
J6/JFH-1 RLuc virus at an MOI of 0.5 in the presence of each compound for 48 h. Cells were lysed and the levels of luciferase assayed as described for Fig. 1. (B)
JFH-1 supernatants were produced by electroporation of cells with JFH-1 RNA and collection of the media from repeated passages for 2 weeks. Virus inoculum
was clarified by centrifugation and added to Huh7 cells (5  104 cells in six-well plates) in the presence of the indicated compounds. Cells were washed 24 h
postinfection and were treated withmedium plus compound for a further 48 h. Virus supernatants were collected and titrated ontoHuh7 cells to assess numbers
of focus-forming units (FFU)/ml. (C) Sample Western blots from the experiment discussed in panel B immunoblotted for NS5A, core, and GAPDH (loading
control) are shown. (D) Experiments were performed as described for panel B in the presence of KCl and TEA at concentrations assessed in the experiment
illustrated in Fig. 1. (E) Huh7 cells were infected with JFH-1 supernatants for 24 h. Cells were washed and replaced with medium plus compound for a further
48 h. Virus supernatants were collected, and virus production was assessed by focus-forming assays as described for panel B. (F) Compounds were mixed with
virus inoculum in DMEM for 1 h and Huh7 cells infected at 37°C for 3 h. Cells were washed three times in phosphate-buffered saline (PBS) to remove unbound
virus, and virus production was assessed 48 postinfection by focus-forming assays of virus supernatants. AP33 was included in these assays to inhibit HCV entry
(50 mg/ml). All results were calculated relative to values for the untreated controls. **, significant difference from control value (P 0.05); NS, no differences at
the 0.05 significance level.
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23%, and 72%  22% inhibition, respectively). This was paral-
leled by a decrease of both NS5A and core protein expression in
virus lysates as assessed by Western blot analysis (Fig. 3C). No
effects on JFH-1 virus production were observed when TEA or
KCl was assessed in these assays (Fig. 3D). We subsequently per-
formed time-of-addition focus reduction assays using JFH-1 virus
inoculum to assess the effects of DIDS over the time course of
HCV infection.Cells were treatedwith each inhibitor 24 hp.i., and
virus production was assessed 72 h p.i. Figure 3E shows that DCV,
NPPB, and IAA-94 reduced JFH-1 virus production when added
postinfection (92% 9%, 81% 23%, and 72% 22% inhibi-
tion, respectively), consistent with a block of HCV replication.
DIDS however, failed to reduce virus production relative to that in
the untreated wells, consistent with a lack of inhibition of HCV
replication. To further determinewhich steps of theHCV life cycle
are impaired by DIDS, we examined the effects of each Cl chan-
nel inhibitor on virus entry by adding them to JFH-1 inoculum
during the initial 3 h of virus infection (26). The HCV-neutraliz-
ing mouse monoclonal E2 antibody AP33, a characterized inhib-
itor of HCV entry, was included in these assays for verification
(27). Figure 3F shows that, while AP33 (50g/ml) inhibited HCV
entry by 72%  11%, IAA-94, NPPB, and DIDS did not impede
FIG 4 Assessment of the Cl channel(s) required for HCV replication. (A) Expression of CLIC-1, ClC-2, ClC-3, ClC-5, and ClC-7 was ablated by transfection
of 75 pmol siRNA, as demonstrated by RT-PCR using whole-cell RNA extracts from SGR–Feo–JFH-1 cells. The siRNAhadminimal impact on levels of GAPDH.
(B) SGR–Feo–JFH-1 cells were treated with Cl channel siRNA or control siRNA, and luciferase expression was assessed as described for Fig. 1. Results were
calculated relative to values for the transfection reagent-only controls. Error bars represent the SEM from three independent experiments. **, significant
difference from the control value (P 0.05); NS, no differences at the 0.05 significance level. (C) Huh7 cells were treated with Cl channel siRNA or control
siRNA for 48 h and infected with J6/JFH-1 RLuc virus at anMOI of 0.5 for 48 h. Cells were lysed and the levels of luciferase assayed as described for Fig. 1. Error
bars represent the SEM from four independent experiments. Values are normalized to those for the transfection controls. **, significant difference from value for
the untreated control (P 0.05). NS, no differences at the 0.05 significance level.
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viral entry. These observations suggest that a DIDS-sensitive Cl
channel can inhibit early postentry virion trafficking and/or early
replication events but does not inhibit virus entry or replication
following the establishment of infection.
Given these data, we investigated the molecular identity of the
Cl channel(s) required during theHCV life cycle. To date, nearly
40 different genes that, when expressed, increase Cl conductance
have been cloned. These include the Cl intracellular-channel
(CLIC) proteins cyclic AMP (cAMP) (CFTR)-, calcium (CaCC)-,
voltage-activated Cl channels andCl/H exchangers (CLCs) as
well as ligand-gated Cl channels [GABA(A), GABA(C), and gly-
cine]. In hepatocytes, CLIC-1, ClC-2, ClC-3, ClC-5, andClC-7 are
expressed (9). We confirmed this by reverse transcription-PCR
(RT-PCR) analysis (primer sequences are available upon request)
and silenced this expression through small interfering RNA
(siRNA) transfection (Fig. 4A). Figure 4B shows that ClC-2,
ClC-3, ClC-5, and ClC-7 silencing significantly suppressed SGR–
Feo–JFH-1 replication (52% 6%, 31% 16%, 48% 2%, and
50% 10% inhibition of luciferase activity, respectively). CLIC-1
knockdown displayed no discernible effects. Since some of these
CLC channels and transporters are sensitive toNPPB and IAA-94;
this confirmed the importance of Cl influx during HCV replica-
tion.
We finally investigated the effect of Cl channel silencing on
J6/JFH-1 RLuc virus infection. Consistently with what occurred
with SGR–Feo–JFH-1, silencing of ClC-2 and ClC-3 inhibited lu-
ciferase expression by 50% 21% and 52% 17%, respectively,
confirming their requirement for virus replication. However,
whenClC-5 andClC-7 were silenced, no effects on J6/JFH-1 RLuc
luciferase activity were observed despite their inhibitory effects on
SGR–Feo–JFH-1 replication. Conversely, silencing of CLIC-1 de-
creased J6/JFH-1 RLuc luciferase activity by 46% 11% (Fig. 4C)
despite a lack of effect on the replication of SGR–Feo–JFH-1
(Fig. 4B).
It is interesting to address what might be the molecular mech-
anisms underpinning the differential effects of CLIC-1, ClC-5,
and ClC-7 silencing. While data on the biological role of CLIC-1
are limited, its activity has been shown to be required for the
regulation of endosomal/lysosomal pH (9, 28). This may explain
our observations, since the acidic late endosome/lysosome pH is
crucial for induction of HCV glycoprotein (E1/E2) membrane
fusion during early HCV postentry events to allow HCV genome
release (29). The fact that ClC-5 and -7 are dispensable for J6/
JFH-1 RLuc infectivity suggests that their function may be com-
pensated for by HCV core-NS2 expression. ClC-5 is a known
2Cl/H exchanger rather than a Cl channel, the function of
which is to control endosomal acidification (30, 31). The HCV
viroporin p7 is thought to form cationic intracellular channels
that promote a global loss of organelle acidity (32, 33). p7 activity
may thus prevent the buildup of an excess positive charge in spe-
cific organelles, a principle typically achieved by the import of Cl
via anion transporters, including ClC-5.
Considering our findings together, we have confirmed the role
of several Cl channel proteins during theHCV life cycle. Of note,
we have identified ClC-2 and ClC-3, whose activities are required
during HCV replication. Endosomal acidification and [Cl]i ac-
cumulation are significantly impaired in hepatocytes from ClC-
2/3 knockout mice (20), and fractionation studies have suggested
that these channels reside in early/late endosomes (34). The orga-
nization, composition, and functions of membrane structures in-
duced by positive-strand RNA viruses remain largely ill defined
but are generally accepted to require endosome integrity to recruit
endosomal host cell factors and concentrate virus proteins to pro-
duce viral factories. Here, for the first time, we implicate host cell
Cl influx through CLC channels/transporters during this pro-
cess. The challenge will now be to define the specific virus-host
interactions that require Cl channel functionality.
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